anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
A prodrug composition containing a cinnamate moiety and a biologically active molecule moiety which can be released by hydrolysis or activated by light is disclosed. The cinnamate moiety can have substituents of various electronically donating or electronically withdrawing groups to modify the cinnamate moiety&#39;s electric properties as well as photo reactivities for the purpose of achieving a proper hydrolysis rate of the acyl bond between the biologically active molecule moiety and the cinnamic acid backbone. The biologically active molecule can be any biologically active agent or diagnostic, for example, a chemotherapeutic such as a paclitaxel, campotothecin, doxorubicin, amethopterin, etoposide, or fluconazole. The prodrug composition can be modified to add a carrier moiety on the prodrug composition for targeting or to facilitate uptake of the drug. The prodrug compositions can be activated with an energy source to release the drug at the desired site. Representative energy sources can be in the form of electric force, ultrasound, light or radiation of a radioactive material which can be administered either externally or internally.
The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin&#39;s lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.
The invention provides compositions comprising formula 1 steroids, e.g., 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations. ® KIPO &amp; WIPO 2007
The present invention relates to a Yanzizhang Chinese medicine blood sugar reduction preparation and a preparation method thereof. A main blood sugar reduction ingredient in the preparation is 3-methyl-2-butanyl isoguanidine which is firstly discovered and is a natural blood sugar reduction compound. The molecular formula of the 3-methyl-2-butanyl isoguanidine is C6H13N3, the molecular weight is 127.18, and the melting point is 108 DEG C. The preparation also contains an auxiliary ingredient for treating diabetes and a mixture of beta-sitosterol, D-mannitol, potassium chloride and sodium chloride. The preparation technology can adopt a boiling method in water, a boiling alcohol deposition method in water, and a macroporous resin desorption method. A preparation prepared by each method is the blood sugar reduction preparation of the present invention. However, the methods are different, and the yield and the content are different. When the blood sugar reduction preparation is prepared, a method can be adopted as required. The effect of blood sugar reduction of the preparation is obvious, and the improvement of patient&#39;s integral functions is obvious.
The present invention discloses a system and method for improving the quality of life in canines and other domesticated animals. As animals age testosterone and other supportive hormones diminish causing reduced activity, a lack of mobility, decreased bone density, and general well-being. Precursor compositions are selected and designed for the purpose of formulating non-toxic therapeutic hormone supplements for oral consumption. The process and method of this invention is comprised of therapies produced from two or more selected non-toxic prohormones that combine during digestion and delivered through a chewable and edible gummy treat. As such there is no requirement for changing the subject&#39;s current diet. The present invention features a continuous low dose supplementation to be incorporated daily whereby dosages are correlated according to the subject&#39;s age, weight, sex, and breed.
The invention relates to a controlled release preparation of bezafibrate. The controlled release preparation of bezafibrate contains a bezafibrate core and a semi-permeability film coating. The outer layer of the semi-permeability film coating is provided with a pore. The semi-permeability film coating is made of following components by mass proportion: 60 to 80 percent of polymer materials of the semi-permeability film coating and 20 to 40 percent of plasticizer. The polymer materials of the semi-permeability film coating are made by the mixture of one or more than one of cellulose acetate, ethyl cellulose, cellulose propionate, polycarbonate, polythene and PVA. The controlled release preparation of bezafibrate overcomes the &#39;peak valley&#39; phenomenon of blood concentration existing in a common preparation and only needs to be taken once per day with the little adverse effect of a gastrointestinal tract, so a curative effect is ensured and patient compliance is also improved. The invention also relates to a preparation method of the controlled release preparation of bezafibrate.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a nebulizer system capable of providing an effective and optimum service to a home-care patient.  &lt;P&gt;SOLUTION: The nebulizer 1 includes a peak flow meter to measure the respiratory function of the patient, and the nebulizer being an inhalation device of a medical solution. The patient inhales in through a blow-in part 18 of the peak flow meter to measure the respiratory function and inhales the medical solution in a medical solution bottle 14 inserted into the insertion port 13 of the medical solution bottle through a nebulizer inhalation port 16. The open air is simultaneously measured by a temperature sensor 19 and a humidity sensor 20. These measurement data and inhalation record data are transmitted to a server from an outside connection part and health sites of the patient based on the data are opened on a network. The patient can receive suitable instruction from a doctor on the network and also receive the supply of the medical solution from a service pharmacy at an appropriate timing.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
A computing server may use one or more recommender systems to predict phenotypes of individuals based on survey responses, other phenotypes, environmental factors, and genetic data of the individuals. The computing server may retrieve survey responses of a set of individuals regarding a set of phenotypes of the individuals. The computing server may construct a matrix that includes the values of the phenotypes. The computing server may predict an undetermined phenotype of a target individual using collaborative filtering, which provides the prediction based on other phenotypes of the target individuals and based on at least another individual&#39;s phenotypes. The computing server may also predict a target phenotype based on the phenotype of other individuals who are similar to the target individual. The computing server may determine another individual is similar to the target individual based on the length of identity-by-descent (IBD) segments between the two individuals.
FIELD: veterinary virology. SUBSTANCE: vaccine strain &#34;ЛТ&#34; of cattle plague virus is grown on saiga kidney cell transplanted line in roller culture and inactivated with copper sulfate at final concentration 0.1-0.2% at 36-38 C for 22-26 hr. Inactivated vaccine is tested under laboratory and industrial conditions. Vaccine is harmless and nonreactogenic at its administration to rabbits, piglets, yaks and cattle and shows high antigenic and immunogenic properties. After two-fold vaccination (at 10-14 days interval) preparation causes formation of humoral immunity and resistance to infection with virulent strain of cattle plague in cattle. EFFECT: high effectiveness of vaccine. 1 tbl
This invention relates to a compound  &lt;IMAGE&gt;  in which R1 represents a 1,2,3,6-tetrahydro-1-pyridyl radical substituted in the 4-position by (a) a phenyl radical, (b) a phenyl radical substituted by a halogen atom or an alkyl, hydroxy or alkoxy radical, (c) a 3-indolyl radical, (d) a 3-indolyl radical substituted on the nitrogen atom by an alkyl or alkylcarbonyl radical and/or in the 5-position by a halogen atom or (e) a 3-(5-hydroxyindolyl) radical. a 1-piperazinyl radical substituted in the 4-position by (a) a phenyl radical, (b) a phenyl radical substituted by an alkoxy, alkyl, hydroxy, nitro or amino radical or a halogen atom, (c) a 1,2-benzisothiazol-3-yl radical, (d) a 1,2-benzisoxazol-3-yl radical or (e) a 2-pyridyl radical. a piperidino radical substituted in the 4-position by (a) a phenyl radical, (b) a phenyl radical substituted by a halogen atom or a hydroxy, alkyl or alkoxy radical, (c) two phenyl radicals, (d) a bis(4-fluorophenyl)methylene radical, (e) a 4-fluorobenzoyl radical, (f) a 2-oxo-1-benzimidazolinyl radical, (g) a 2-oxo-1-benzimidazolinyl radical substituted in the 3-position by an alkylcarbonyl or benzoyl radical, (b) a hydroxy radical and a phenyl radical optionally substituted with an alkyl, alkoxy or hydroxy radical or a halogen atom, (i) a 3-indolyl radical, (j) a 3-indolyl radical substituted on the nitrogen atom by an alkyl or alkylcarbonyl radical and/or in the 5-position by a halogen atom or (k) a 3-(5-hydroxyindolyl) radical. either: R2 and R3, which are identical, represent a hydrogen or halogen atom and R4 represents a hydrogen atom or R2 and R4 represent a hydrogen atom and R3 represents a halogen atom or an acetylamino radical or R2 and R3 represent a hydrogen atom and R4 represents a halogen atom and R5 represents a -CH= group. or R2, R3 and R4 represent a hydrogen atom and R5 represents a nitrogen atom. R6 represents an alkylene chain containing 2 to 4 carbon atoms or a propylene chain substituted in the 1- or 3-position by an alkyl radical or in the 2-position by an alkyl, alkoxy, hydroxy, dialkylamino, piperidino, morpholino or thiomorpholino radical, with the reservation that when R6 represents a propylene radical substituted in the 2-position by a dialkylamino, piperidino, morpholino or thiomorpholino radical, R1 cannot be a radical containing a hydroxy radical, and their salts, are useful in therapy for their ability to block serotonin receptors.
PURPOSE: To obtain an agent for expanding coronary artery, protecting vascular endothelium, suppressing the blood lipid concentration or treating hypertension by using an adenosine derivative as an active component. CONSTITUTION: The objective agent contains a compound of the formula I (R1 is allyl, methallyl, a 3-7C alkynyl, a 3-8C cycloalkyl, a halogen, phenyl, etc.; R2 is H, a 1-4C alkyl, a 3-5C cycloalkyl or a halogen; R3 is a 1-4C alkyl), e.g. 6-cyclopentyl-2&#39;-O-methyladenosine as an active component. The compound of the formula I is a new substance and producible by reacting a compound of the formula II (X is a halogen) with a compound of the formula R1 -NH2 in a solvent such as dioxane at 80-120 deg.C. It can be formulated in the form of oral or parenteral drug and the administration dose of the compound is 0.5-250 mg/day.
4-Halo-etianic acids and derivations of the formula: &lt; CHEM &gt; wherein X&lt;1&gt; is fluoro or chloro X&lt;2&gt; is fluoro, chloro or hydrogen X&lt;3&gt; is fluoro, chloro, bromo or hydrogen X&lt;4&gt; is =C=O or &lt; CHEM &gt; of may be &lt; CHEM &gt; when X&lt;3&gt; is chloro R is hydrogen, alkyl of one to six carbon atoms optionally substituted with one halo, or phenyl or benzyl optionally substituted on the phenyl ring with a substituent selected from alkyl of one to four carbon atoms, alkoxy of one to four atoms and halo R&lt;1&gt; is hydrogen or alkanoyl of 2 to 6 carbon atoms R&lt;2&gt; is hydrogen, alpha -methyl or beta -methyl and the solid and broken lines between C-1 and C-2 represent a double or a single bond. The compounds wherein R is other than hydrogen are useful as anti-inflammatory agents. They can be prepared by esterifying the corresponding acid. The 17 alpha -esters can be prepared by esterifying the corresponding 17 alpha -hydroxy compounds. The 17ss-carboxylic group can be introduced by oxidising the corresponding 20-oxo-21-hydroxy (or alkanoyloxy) compound. The double bond at the 4,5 position is produced by contacting the corresponding DELTA &lt;5&gt; compound with a base.
285,087. I, G. Farbenindustrie Akt.- Ges. Feb. 11, 1927, [Convention date]. Toxins, vaccines, and immunizing and like serums.-Tuberculin preparations are treated with heavy metal compounds such as dialysed iron oxychloride or lead salts so as to remove albumins and their cleavage products leaving the active constituents in the solution, from which they may be separated by addition, either of acetone, an alcohol, or other solvent in which the active substances are insoluble, or of an alkaloil precipitant which is afterwards eliminated by chemical action. In one example, dry human tuberculin separated from Koch&#39;s broth by precipitation with alcohol, or old tuberculin &#34; Koch,&#34; is dissolved in water, and dialysed ferric hydroxide added to precipitate albumin. The concentrated filtrate is treated with picric acid and the precipitate decomposed with dilute hydrochloric acid. Acetone is added to the solution obtained so as to precipitate the active substances. In a second example an extract of bovine tubercule bacilli freed from wax and fat is dissolved in water and the solution treated with lead acetate. The filtrate is freed from lead and treated with acetone. Specifications 21927/93 and 1398/10 are referred to. The Specification as open to inspection under Sect. 91 (3) (a) contains also a third example, according to which killed bacilli are extracted with alcohol and the solution evaporated under vacuum. The residual mass is extracted with water and the solution obtained treated as in the second example. This subject-matter does not appear in the Specification as accepted.
PURPOSE:The titled drug capable of being directly inserted and applied to the affected part, obtained by pulverizing polyglycollic acid or a glycollic acid- lactic acid copolymer, deaerating and drying it under reduced pressure, blending it with a drug, preheating the blend, feeding it to a mold at constant temperature under pressure, molding it. CONSTITUTION:Polyglycollic acid or a glycollic acid-lactic acid copolymer having &gt;=80wt% polyglycollic acid is pulverized, deaerate and dried at 100-200 deg.C under 5-10mm.Hg reduced pressure for 2-3hr, low-volatile components in the polymer are completely volatilized. 100pts.wt. above-mentioned polymer is mixed with 20-40pts.wt. drug (e.g., carcinostatic agent such as 5-fluorouracil, etc.), preheated, fed to a mold kept at 195-235 deg.C, and molded into a needle-like material having 1.5mm. diameter and about 3cm length. The strength of the molded drug is raised by the deaeration treatment, and low-boiling organic impurities and air will not get into the body.
The invention discloses a Chinese medicinal enema for treating a chronic pelvic inflammatory disease. The pelvic inflammatory disease belongs to the field of &#39;bellyache&#39;, &#39;abnormal vaginal discharge&#39; and the like in traditional Chinese medical science. The pathogenesis of the pelvic inflammatory disease mainly includes &#39;dampness, heat and stasis&#39;. In the invention, Chinese medicines including baikal skullcap root, ash bark, honeysuckle flower, common andrographis herb, heartleaf houttuynia herb, kadsura pepper stem, kusnezoff monkshood root, nutgrass galingale rhizome, rose, myrrh, twotooth achyranthes root and safflower which have the effects of clearing heat, promoting diuresis, dispersing blood stasis and dredging collateral are selected, and are prepared into an enema by the preparation department of the academy. The enema is applied to a patient every night before sleeping. As proved by clinical test, the total effective rate is 96.7 percent, which is remarkably higher than that of a control group; and moreover, the Chinese medicinal enema is free from toxic and side effects, has low treatment cost, and is safe and reliable.
PROBLEM TO BE SOLVED: To produce an expandable composition, capable of moderately controlling the elution of an active ingredient and imparting a refreshing feeling when administering the composition and utilizable for foods, medicines, agrochemicals, etc., by combining a specific nucleated powder containing a physiologically active ingredient with an expandable ingredient. SOLUTION: This expandable composition is obtained by using a nucleated powder prepared by coating a core of a fine granule having about &lt;=5ml/g specific volume with a coating layer containing a water-soluble polymer and a physiologically active substance unstable to acids and an enteric coating layer and having about &lt;=300μm average grain diameter, an expanding ingredient and an expansion assistant in combination. At this time, the content of the expansion assistant used is 1.0-2.0 equiv. based on 1N expanding ingredient. A physiologically inert substance or spherical substance is preferred as the fine granular core. A cellulosic derivative is preferred as the water- soluble polymer and the content thereof is about 0.1-50wt.% based on the whole nucleated powder. A benzimidazole-based medicine is preferred as the physiologically active substance.  The amount of the enteric coating layer is about 30-50wt.% based on the whole nucleated powder and that of the expanding ingredient is about 10-2,500 pts.wt. based on 100 pts.wt. nucleated powder.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a diagnostic result reporting method which can make a diagnosis based upon biological information measured by an expensive biological information measuring instrument without owning the expensive biological information measuring instrument and report the result of the diagnosis without imposing any burden on a patient.  &lt;P&gt;SOLUTION: The biological information that the patient has obtained at a biological information measuring institution 20 is stored on a server 24, which transmits the stored biological information of the patient to a doctor terminal device 18 of a doctor who diagnoses the patient. The doctor can generate a diagnosis result according to the set biological information, so the doctor need not own the expensive biological information measuring instrument 32. Further, the doctor sends the diagnosis result from the doctor terminal device 18 to the server 24. The server 24 stores the sent diagnosis result and sends the diagnosis result to the patient terminal device 14 according to a diagnosis result request signal from the patient terminal device 24. The patient, therefore, need not see the doctor to know the diagnosis result.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
PROBLEM TO BE SOLVED: To obtain an immunosuppressive agent containing an oligosaccharide or its derivative as an active component, having little side effect, prepared in a drug form or a food form and especially useful for suppressing the activity of B- and T-lymphocytes. SOLUTION: This immunosuppressive agent contains a compound having a group bound to a reducing-terminal-glucose residue of 3-O-α-D- glucopyranosyl-D-glucose expressed by the formula (R&lt;1&gt; is an organic residue) through an α- or β-glucosyl bonding as an active component. The agent has an activity to suppress B- or T-lymphocyte activation occurring when an immunocompetent cell receives antigen-specific or antigen-non-specific stimulation. The agent is useful for the treatment of an autoimmune disease such as malignant lymphoma, systemic lupus erythematosus or clonic arthrorheumatism, or an allergic disease attributable to the abnormality of B-lymphocytes. Further, the agent also useful for the prophylaxis of rejection in organ transplantation since the agent can suppress the activation of T- lymphocytes.  In the case of a drug, the agent can be administered orally or parenterally, and the daily dose for adult is 4-40mg in terms of an active component in oral administration.
A therapeutic composition for oral and parenteral administration to increase the strength of the capillary blood vessels of living beings comprises an isoflavonic compound of the general formula &lt;FORM:0912198/VI/1&gt; wherein R is hydrogen, a carboxyl group, a non-toxic salt of a carboxyl group with a metal, an amine or an amino-alcohol or an ester thereof associated with an inert therapeutically administrable vehicle which is a solid carrier or a sterile liquid.  Specified sterile liquids are distilled water, isotonic saline solution, vegetable oils and organic solvents.  Solid forms specified are tablets or granules containing starch, fecula, colloidal silica, arabic gum, lactose, talc and magnesium stearate. The compositions may contain a phosphate e.g. disodium or mono potassium mono or dihydrogen phosphate which may be further associated with non-toxic inorganic metal salts e.g. zinc or iron sulphate when the composition is in the form of an aqueous solution. A specified salt of g -hydroxy isoflavene-2-carboxylic acid is the sodium salt.
A preparation for the care of the teeth and mouth, having foaming properties, and which may be of liquid consistency, contains a sulphuric acid ester of a higher aliphatic alcohol or a soluble (sodium) salt thereof and one or more flavourings or perfumes or both in addition to known diluent bases.  Sulphuric acid esters of myristic and lauric alcohols, and of the mixture of alcohols obtained by reduction of cocoa nut oil acids are particularly suitable.  As flavourings or perfumes, oil of peppermint, menthol and lemon oil are specified.  In examples the following other ingredients are specified: tartar dissolving acids, e.g. tartaric or citric acid, carragheen mucilage, glycerin, light precipitated calcium carbonate, bolus alba and hydrogen peroxide or percompounds.  Specification 318,610, (as open to inspection under Sect. 91 of the Acts), [Class 81 (i), Disinfecting &amp;c.], 341,979, 350,080, 351,452, and 358,612, (as open to inspection under Sect. 91 of the Acts), [all in Group III], are referred to.